| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/10/2001 | WO2001032621A1 Novel indole derivatives and drugs containing the same as the active ingredient |
| 05/10/2001 | WO2001032618A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032615A1 1,4 substituted piperidinyl nmda/nr2b antagonists |
| 05/10/2001 | WO2001032611A1 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| 05/10/2001 | WO2001032604A1 Activators of soluble guanylate cyclase |
| 05/10/2001 | WO2001032263A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 05/10/2001 | WO2001032222A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | WO2001032220A1 Gene therapy for diabetic ischemic disease |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032214A1 Inhibitors against vascular lipid deposition containing chymase-inhibiting substances |
| 05/10/2001 | WO2001032192A1 Active substance in ganoderma lucidum extract and drugs, health foods and cosmetics containing the same |
| 05/10/2001 | WO2001032179A1 8-aza-bicyclo[3.2.1]octane nmda/nr2b antagonists |
| 05/10/2001 | WO2001032175A1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032171A1 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline nmda/nr2b antagonists |
| 05/10/2001 | WO2001032169A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/10/2001 | WO2001032167A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | WO2001032162A1 Liver selective therapy |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032070A2 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 05/10/2001 | WO2001032036A1 Cholesterol reducing stanol compositions, preparation and method of use |
| 05/10/2001 | WO2001032029A2 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 05/10/2001 | WO2001017959A3 Vitronectin receptor antagonists |
| 05/10/2001 | WO2001005974A3 The il-1l1 gene and polypeptide products |
| 05/10/2001 | WO2001000183A3 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 05/10/2001 | WO2000078778A3 C-pyrazole a2a receptor agonists |
| 05/10/2001 | WO2000077035A3 Novel potassium channels and genes encoding these potassium channels |
| 05/10/2001 | WO2000073276A3 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists |
| 05/10/2001 | WO2000034334A9 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 05/10/2001 | US20010001097 Stress-follower circuit configuration |
| 05/10/2001 | DE19953414A1 Imidazopyridinderivate als Phospodiesterase VII-Hemmer Imidazopyridine derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953025A1 Pyrrolderivate als Phosphodiesterase VII-Hemmer Pyrrole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953024A1 Isoxazolderivate als Phosphodiesterase VII-Hemmer Isoxazole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19952960A1 Verfahren zur Identifizierung von anti-apoptotisch wirksamen Verbindungen A method of identifying anti-apoptotically active compounds |
| 05/10/2001 | CA2389849A1 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 05/10/2001 | CA2389807A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | CA2389773A1 Activators of soluble guanylate cyclase |
| 05/10/2001 | CA2389765A1 Cpg receptor (cpg-r) and methods relating thereto |
| 05/10/2001 | CA2389751A1 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | CA2389704A1 Compositions comprising edible oils and phytosterols and/or phytostanols substantially dissolved therein, method of making the same, and use thereof in treating or preventing cardiovascular disease, and its underlying conditions |
| 05/10/2001 | CA2389690A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | CA2389672A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389643A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 05/10/2001 | CA2389616A1 Liver selective therapy |
| 05/10/2001 | CA2389605A1 Cholesterol reducing stanol compositions, preparation and method of use |
| 05/10/2001 | CA2389439A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
| 05/10/2001 | CA2389226A1 1,4 substituted piperidinyl nmda/nr2b antagonists |
| 05/10/2001 | CA2389184A1 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline nmda/nr2b antagonists |
| 05/10/2001 | CA2388822A1 27 human secreted proteins |
| 05/10/2001 | CA2388354A1 Lactobacillus helvetius producing antihypertensive di- and tripeptides |
| 05/10/2001 | CA2388171A1 8-aza-bicyclo[3.2.1]octane nmda/nr2b antagonists |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387799A1 19 human secreted proteins |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2387613A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them |
| 05/10/2001 | CA2387261A1 25 human secreted proteins |
| 05/10/2001 | CA2387136A1 26 human secreted proteins |
| 05/10/2001 | CA2386938A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2385928A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/10/2001 | CA2385665A1 Modulation of enos activity and therapeutic uses thereof |
| 05/10/2001 | CA2358314A1 Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor |
| 05/10/2001 | CA2324800A1 Use of apo b secretion/mtp inhibitors |
| 05/09/2001 | EP1097945A2 Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| 05/09/2001 | EP1097928A1 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-ones as anti-hyperlipidemics |
| 05/09/2001 | EP1097926A1 Thiobenzimidazole derivatives |
| 05/09/2001 | EP1097920A1 Intermediate for condensed benzazepine derivatives |
| 05/09/2001 | EP1097719A1 NEP inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097718A1 NPY antagonists for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097711A2 Treatment of pulmonary hypertension |
| 05/09/2001 | EP1097710A2 Combination product for treating niddm |
| 05/09/2001 | EP1097707A1 Treatment of female sexual dysfunction |
| 05/09/2001 | EP1097706A1 Phosphodiesterase inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097382A2 Imidazoline receptor binding compounds |
| 05/09/2001 | EP1097241A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 05/09/2001 | EP1097201A1 Snurpotine i human m 3?g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 05/09/2001 | EP1097167A2 Neurotrophic growth factor |
| 05/09/2001 | EP1097165A1 Novel inhibitors of angiogenesis and tumor growth |
| 05/09/2001 | EP1097159A1 Phosphinous and phosphonic acid derivatives used as medicaments |
| 05/09/2001 | EP1097150A1 Imidazolyl derivatives |
| 05/09/2001 | EP1097149A1 Bicyclohexane derivatives |
| 05/09/2001 | EP1097147A1 Novel angiogenesis inhibitors |
| 05/09/2001 | EP1097141A1 Imidazole derivatives with biphenylsulfonyl substitution, method for preparing them and their use as a drug or diagnostic agent |
| 05/09/2001 | EP1097140A2 Biphenylsulfonyl-substituted imidazole derivatives, their preparation process, their use as a drug or diagnostic agent and drug containing them |
| 05/09/2001 | EP1097139A1 Quinoline derivatives |
| 05/09/2001 | EP1097129A1 N-benzocycloalkyl-amide derivatives and their use as medicaments |
| 05/09/2001 | EP1097127A1 Diacylhydrazine derivatives as integrin inhibitors |
| 05/09/2001 | EP1096937A2 Sustained release ranolazine formulations |
| 05/09/2001 | EP1096932A2 Antihypertensive combination of valsartan and calcium channel blocker |
| 05/09/2001 | EP1096919A1 Systems and methods for local delivery of an agent |
| 05/09/2001 | CN1294577A 钾通道抑制剂 Potassium channel inhibitors |
| 05/09/2001 | CN1294006A Process for preparing medicine to cure apoplexy sequelae |
| 05/09/2001 | CN1293981A Hypolipemic 'Tongluowan' |
| 05/09/2001 | CN1293971A Medicine for treating apoplexy and its preparing process |
| 05/09/2001 | CN1293923A Cold ox horn blood tea and its preparing process |
| 05/09/2001 | CN1065531C Aminotetrazole derivatives useful as nitric oxide synthase inhibotors |
| 05/09/2001 | CN1065438C Cyclic adhesion inhibitors |
| 05/08/2001 | US6229025 Process for alkylating hindered sulfonamides |